Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone

Tools

Item Type:	Article
Title:	Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone
Creators Name:	Luedtke, A., Heck, K., Genschel, J., Mehnert, H., Spuler, S., Worman, H.J. and Schmidt, H.H.
Abstract:	Dunnigan-type familial partial lipodystrophy (FPLD) is caused by mutations in LMNA, the gene that encodes nuclear lamins A and C. FPLD is characterized by peripheral fat loss, excess central adiposity, insulin resistance, and hyperlipidaemia, which are difficult to treat. We present our 2 years' experience of treatment with rosiglitazone in a subject with FPLD. Insulin requirement decreased significantly from 240 IU/day to 76 IU/day (range 20-240 IU/day) and serum triglyceride concentration was lowered from 13.7 +/- 14.4 mmol/l to 4.5 +/- 4.3 mmol/l and remained stable. Mean HbA(1c) prior to rosiglitazone therapy was 9.4 +/- 1.32% and decreased to 7.4 +/- 0.6% during therapy with rosiglitazone. This case demonstrates the benefits of PPARgamma-agonists on glycaemic control and dyslipidaemia in a patient with FPLD. This in turn implies that PPARgamma may play a pathophysiological role in FPLD.
Keywords:	Diabetes, Familial Partial Lipodystrophy, Hyperlipidaemia, Insulin Resistance, Thiazolidinedione
Source:	Diabetic Medicine
ISSN:	0742-3071
Publisher:	Wiley-Blackwell
Volume:	22
Number:	11
Page Range:	1611-1613
Date:	November 2005
Official Publication:	https://doi.org/10.1111/j.1464-5491.2005.01757.x
PubMed:	View item in PubMed

Repository Staff Only: item control page